热门资讯> 正文
移植疗法首次商业销售后，Omeros走高
2026-01-28 01:38
- Shares of Omeros Corporation (OMER) gained on Tuesday after the company announced first commercial shipments of Yartemlea, its recently approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem cell transplantation.
- The Seattle, Washington-based biotech received FDA approval in December to market Yartemlea for patients aged two years and above with TA-TMA. A condition linked to hematopoietic stem cell transplantation, TA-TMA, has a more than 90% mortality rate in severe cases.
- Omeros (OMER) stated that the first commercial shipments of Yartemlea began last week, and concurrently, it fulfilled initial orders for the drug received from multiple transplant centers.
- Adults and children with TA-TMA are now undergoing Yartemlea therapy, including those who have failed prior off-label C5-inhibitor regimens in both inpatient and outpatient-based care settings, the company added.
More on Omeros
- Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript
- Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade)
- Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid
- Omeros surges on FDA nod for transplant therapy (update)
- Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart
推荐文章
一周IPO | 新消费IPO再受热捧！鸣鸣很忙首日涨近70%；大族数控、爱芯元智等五只新股正在招股中
打爆所有空头？Sandisk交出的“炸裂财报”再度引爆存储行情！周期或许远未见顶？
财报前瞻 | 4万亿美元市值迎大考！谷歌Q4财报能否为其“AI全栈”野心正名？
新股申购 | 两只新股今起招股！澜起科技一手入场费10796.80港元；爱芯元智一手入场费2848.44港元
华盛早报 | 特朗普今晚公布美联储新主席人选！沃什概率飙升至近8成；金银价格一度闪崩又回弹
美股机会日报 | Meta业绩亮眼盘前大涨9%！英伟达、微软等巨头被曝将向OpenAI投资600亿美元
港股突破28000点，接下来该如何布局？这三大方向尤获机构、北水青睐（附股）
微软Q2业绩会实录：大部分投入资本周期已通过合同锁定
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
